What it means
Oxyntomodulin is made from the same precursor protein as glucagon and GLP-1, in the same intestinal L-cells. It is released after meals and acts weakly on both the GLP-1 receptor and the glucagon receptor.
Small human studies in the 2000s found that oxyntomodulin injections reduced food intake and increased energy use. Like natural GLP-1, though, it breaks down within minutes, so it cannot be used as a medicine on its own.
That two-receptor profile became a blueprint. Drug makers engineered longer-lasting molecules with balanced GLP-1 and glucagon activity. Mazdutide is often described as an oxyntomodulin analog, and survodutide works on the same pair of receptors.
No oxyntomodulin product is FDA-approved. Mazdutide is approved in China, and survodutide was still in phase 3 trials at our last review, so the approach is not yet available as a US medicine.
Why it matters
Oxyntomodulin is the natural model for the glucagon and GLP-1 dual agonists now in late-stage trials.
Related terms
Sources
Clinician review pending. Drafted from primary sources and waiting for sign-off by a licensed clinician (MD, DO or PharmD) before launch. Every number is checked against its source. Drug facts are re-checked quarterly, prices monthly and whenever a label changes. How we review · Report an error